Chromosome 3p tumor-suppressor gene alterations in cervical carcinomas

Molecular Carcinogenesis

Volumn 30, Issue 3, 2001, Pages 159-168

  Herzog, Christopher R ^a   Crist, Keith A ^b   Sabourin, Carol L K ^c   Kelloff, Gary J ^d   Boone, Charles W ^d   Stoner, Gary D ^c   You, Ming ^b,c,e  

^a AMERICAN HEALTH FOUNDATION   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e OHIO STATE UNIVERSITY   (United States)

Author keywords

3p; Cervical carcinoma; Fragile histidine triad; Loss of heterozygosity; Transforming growth factor ; type II receptor

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; GENE PRODUCT; PROTEIN VON HIPPEL LINDAU; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA2 RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CHROMOSOME 3P; CONTROLLED STUDY; GENE DELETION; GENE LOCUS; GENE MAPPING; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SILENT GENE; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA;

ACID ANHYDRIDE HYDROLASES; ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; CHROMOSOMES, HUMAN, PAIR 3; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; MUTATION; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTEINS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, MESSENGER; UTERINE CERVICAL NEOPLASMS;

EID: 0035063353     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.1024     Document Type: Article

References (50)

1. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective
2. Cervical intraepithelial neoplasia and cervical cancer
3. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines
4. Allelotype analysis of cervical carcinoma
5. Genomic alterations in cervical carcinoma: Losses of chromosome heterozygosity and human papilloma virus status
6. Allelotyping of all chromosome arms in invasive cervical cancer
7. Loss of heterozygosity on the short arm of chromosome 3 in carcinoma of the uterine cervix
8. Report on the committee on chromosome and gene loss in human neoplasia
9. Deletion mapping of chromosome 3p in female genital tract malignancies using microsatellite polymorphisms
10. Deletion mapping of chromosome 3p in human uterine cervical cancer
11. High resolution analysis of chromosome 3p alterations in cervical carcinoma
12. Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma
13. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability
14. A transforming growth factor β receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability
15. Mutation and downregulation of the transforming growth factor β type II receptor gene in primary squamous cell carcinomas of the head and neck
16. Mutational analysis of the transforming growth factor β receptor type II gene in human ovarian carcinoma
17. Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: An immunohistochemical study
18. Inactivation of the transforming growth factor beta type II receptor in human small cell lung cancer cell lines
19. Reduced transforming growth factor-beta type II receptor (TGF-beta RII) expression in adenocarcinoma of the lung
20. The transforming growth factor-β family
21. TGFβ signal transduction
22. Controlling TGF-beta signaling
23. Progressive loss of sensitivity to growth control by retinoic acid and transforming growth factor-β at late stages of human papillomavirus type 16-initiated transformation of human keratinocytes
24. Differential response of cervical intraepithelial and cervical carcinoma cell lines to transforming growth factor-beta 1
25. Resistance to inhibition of cell growth by transforming growth factor β and its role in oncogenesis
26. DPC4, a candidate tumor suppressor gene at chromosome 18q21.1
27. Transforming growth factor-beta 1 is a new form of tumor suppressor with true haploid insufficiency
28. Genetic integrity of transforming growth factor beta (TGF-beta) receptors in cervical carcinoma cell lines: Loss of growth sensitivity but conserved transcriptional response to TGF-beta
29. Structural alterations of transforming growth factor-beta receptor genes in human cervical cancer
30. The human FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcimoma associated translocation breakpoint, is abnormal in digestive tract tumors
31. The FHIT gene is abnormal in lung cancer
32. The FHIT gene at 3p14.2 is abnormal in breast carcinomas
33. FHIT gene alterations in head and neck squamous cell carcinomas
34. FHIT gene expression in human ovarian, endometrial, and cervical cancer cell lines
35. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors
36. Abnormal Fhit expression in malignant and premalignant lesions of the cervix
37. The role of the FHIT/FRA3B locus in cancer
38. Involvement of band 3p14 in t(3;8) hereditary renal carcinoma
39. Translocation t(3;8)(p14.2;q24) in renal cell carcinoma affects expression of the fragile site at 3p14 (FRA3B) in lymphocytes
40. 3-triphosphate hydrolase
41. Replacement of Fhit in cancer cells suppresses tumorgenicity
42. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression
43. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control
44. Kip1 is haplo-insufficient for tumour suppression
45. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer
46. Kip1 protein: Prognostic implications in primary breast cancer
47. Transforming growth factors beta 1 and 2 transcriptionally regulate human papillomavirus (HPV) type 16 early gene expression in HPV-immortalized human genital epithelial cells
48. Regulation of growth and gene expression in human papillomavirus-transformed keratinocytes by transforming growth factor-β: Implications for the control of papillomavirus infection
49. FHIT mutations in human primary gastric cancer
50. Muir-Torre-like syndrome in Fhit-deficient mice